MiraJ. G.: Is it worth while to treat Peyronie's disease?Urology, 16; 1 (1980).
6.
BredaG., GraziottiP., ArtibaniW., LemboA., PaganoF.: Long term follow-up of Peyronie's disease. J. Androl., 5; 145 (1984).
7.
BredaG., GraziottiP., CalabròA., GuazzieriS., TotoA., LemboA.: La terapia dell'induratio penis plastica: nostro attuale orientamento. Quad. Sessuol. clin. (in press).
8.
GustafsonH., JohanssonB., EdsmyrF.: Peyronie's disease: experience of local treatment with Orgotein. Eur. Urol., 7; 346 (1981).
9.
BartschG., Menander-HuberK. B., HuberW., MarbergerH.: Orgotein, a new drug for the treatment of Peyronie's disease. Eur. J. Rheumatol. Inflam., 4; 250 (1981).
10.
HuberW., SchulteT. L., CarsonS., GoldhammerR. E., VoginE. E.: Some chemical and pharmacological properties of a novel anti-inflammatory protein. Toxicol. Appl. Pharmacol., 12; 308 (1968).
11.
HuberW., Menander-HuberK., SaiferM. G. P., DangP. H. C.: Studies on the clinical and laboratory pharmacology of drug formulations of bovine Cu-Zn superoxdie dismutase (Orgotein). In: Willoughby, Giroud, Valo: Perspectives in inflammation, p. 527. Univ. Pack Press, Baltimore1977.
12.
FriedrichM., ClaussenC. D., FelixR.: Immersion ultrasonography of scrotal and testicular pathology. Eur. J. Radiol., 1; 60 (1981).
PisaniE., MantovaniF., PatelliE.: Orgoteina per infiltrazione e per ionoforesi nel trattamento della Induratio Penis Plastica. Atti Soc. it. Urol., Verona1983.
18.
DannerH., FrickJ.: Experiences with orgotein in the treatment of Peyronie's disease. Prog. Reprod. Biol. Med., 9; 50:53. Karger, Basel 1983.
19.
SchillingA., ChaussyC., StaehlerG., BrandiH.: Preliminary evaluation of superoxide dismutase (Orgotein) in the treatment of Peyronie's disease. Prog. Reprod. Biol. Med., 9; 54:56. Karger, Basel 1983.
20.
FurlowW., SwensonH., LeeR.: Peyronie's disease: a study of its natural history and treatment with orthovoltage radiotherapy. J. Urol., 146; 69 (1973).
21.
WilliamsJ., ThomasG.: The natural history of Peyronie's disease. J. Urol., 103; 75 (1970).